Search

Your search keyword '"Immunosuppressive Agents pharmacology"' showing total 850 results

Search Constraints

Start Over You searched for: Descriptor "Immunosuppressive Agents pharmacology" Remove constraint Descriptor: "Immunosuppressive Agents pharmacology" Topic graft rejection Remove constraint Topic: graft rejection
850 results on '"Immunosuppressive Agents pharmacology"'

Search Results

1. Carvacrol ameliorates skin allograft rejection through modulating macrophage polarization by activating the Wnt signalling pathway.

2. Capecitabine mitigates cardiac allograft rejection via inhibition of TYMS-Mediated Th1 differentiation in mice.

3. Rapamycin Prevents Expansion of Costimulation Blockade-resistant CD8+ Alloreactive Memory Cells following Depletional Induction in Renal Transplant Recipients.

4. IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice.

5. A novel FK506-loading mesoporous silica nanoparticle homing to lymph nodes for transplant rejection treatment.

6. Manipulating adrenergic stress receptor signalling to enhance immunosuppression and prolong survival of vascularized composite tissue transplants.

7. T and B lymphocyte dynamics after genetically-modified pig-to-baboon kidney xenotransplantation with an anti-CD40mAb-based immunosuppressive regimen.

8. A study of the mechanisms responsible for the action of new immunosuppressants and their effects on rat small intestinal transplantation.

9. Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation.

10. The Role of Interleukin-6 (IL-6) in the Systemic Inflammatory Response in Xenograft Recipients and in Pig Kidney Xenograft Failure.

11. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs.

12. Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model.

13. The Mandible Ameliorates Facial Allograft Rejection and Is Associated with the Development of Regulatory T Cells and Mixed Chimerism.

14. Anti-C5 Antibody Tesidolumab Reduces Early Antibody-mediated Rejection and Prolongs Survival in Renal Xenotransplantation.

15. Immunological Determinants of Liver Transplant Outcomes Uncovered by the Rat Model.

16. Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept.

17. Rapamycin delays allograft rejection in obese graft recipients through induction of myeloid-derived suppressor cells.

18. Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.

19. What Therapeutic Regimen Will Be Optimal for Initial Clinical Trials of Pig Organ Transplantation?

20. Unraveling the Crucial Roles of FoxP3+ Regulatory T Cells in Vascularized Composite Allograft Tolerance Induction and Maintenance.

21. Effect of Inhibition of the JAK2/STAT3 Signaling Pathway on the Th17/IL-17 Axis in Acute Cellular Rejection After Heart Transplantation in Mice.

22. mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction.

23. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.

24. Impact of Belatacept Conversion on Renal Function, Histology, and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection.

25. Thirty Years of Tacrolimus in Clinical Practice.

26. Artemisinin Attenuates Transplant Rejection by Inhibiting Multiple Lymphocytes and Prolongs Cardiac Allograft Survival.

27. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.

28. CHBP induces stronger immunosuppressive CD127 + M-MDSC via erythropoietin receptor.

29. Evaluation of the immunomodulatory and anti-inflammatory activity of Bakuchiol using RAW 264.7 macrophage cell lines and in animal models stimulated by lipopolysaccharide (LPS).

30. Comprehensive Analysis of Cardiac Xeno-Graft Unveils Rejection Mechanisms.

31. Leflunomide Inhibits rat-to-Mouse Cardiac Xenograft Rejection by Suppressing Adaptive Immune Cell Response and NF-κB Signaling Activation.

32. Hepatocyte growth factor mediates a novel form of hepatic stem/progenitor cell-induced tolerance in a rat xenogeneic liver rejection model.

33. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.

34. The Immunological Basis of Liver Allograft Rejection.

35. Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy.

36. Myeloid-derived suppressor cells in transplantation tolerance induction.

37. Nanoparticle Platforms for Antigen-Specific Immune Tolerance.

38. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.

39. Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts.

40. PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature.

41. Effects of Antirejection Drugs on Innate Immune Cells After Kidney Transplantation.

42. A Novel Immunosuppressant, Luteolin, Modulates Alloimmunity and Suppresses Murine Allograft Rejection.

43. Successful optimization of antiretroviral regimens in treatment-experienced people living with HIV undergoing liver transplantation.

44. Bortezomib ameliorates acute allograft rejection after renal transplant by inhibiting Tfh cell proliferation and differentiation via miR-15b/IRF4 axis.

45. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.

46. The past, present, and future of costimulation blockade in organ transplantation.

47. ASP1126, a Novel Sphingosine-1-Phosphate-Selective Agonist With a Favorable Safety Profile, Prolongs Allograft Survival in Rats and Nonhuman Primates in Combination With Tacrolimus With a Broad Safety Margin for Bradycardia.

48. Delivery of Rapamycin Using In Situ Forming Implants Promotes Immunoregulation and Vascularized Composite Allograft Survival.

49. Inducible IL-7 Hyperexpression Influences Lymphocyte Homeostasis and Function and Increases Allograft Rejection.

50. Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives.

Catalog

Books, media, physical & digital resources